Akero Therapeutics

Metabolic dysfunction-associated steatohepatitis (#MASH) is a severe form of liver disease in which excess fat builds up in the liver and causes inflammation and cell damage that can eventually lead to scarring (fibrosis) and liver failure. A recent article from Liver Disease News highlights recruitment efforts for our Phase 3 #SYNCHRONY program assessing investigational drug #EFX in patients with MASH: https://lnkd.in/eEWzN9QX If you’re interested in learning more about our innovative approach or more about the SYNCHRONY clinical trials, visit: https://lnkd.in/gevAnhqt

Mark your calendars for Akero’s upcoming presentation at the Morgan Stanley Annual Global Healthcare Conference next Wednesday. A live webcast will be available through the investors/events & presentations section of our site, with an archived replay available if you aren’t able to make it live. Learn more: https://lnkd.in/gx6QafHu

Today Akero reported Q2 2024 financial results and provided business updates. Read more at: https://lnkd.in/evUJUX2F

🎆 Happy #4thofJuly from Akero! #IndependenceDay

Mark your calendars for our oral presentation at the Extracellular Matrix Pharmacology Congress on Wednesday. Look for Erik Tillman, PhD as he shares data on the effects of #EFX on remodeling the extracellular matrix in the liver of patients with F2-F3 MASH. #ECM2024

Akero joins the Global Liver Institute on Global Fatty Liver Day to raise awareness about metabolic dysfunction-associated steatotic liver disease (#MASLD) and its more severe form metabolic dysfunction-associated steatohepatitis (#MASH). At Akero, we're dedicated to developing novel therapeutics for patients with MASH, a serious condition that can be life-threatening. 👉 We encourage you today and every day to learn more about MASH, and the importance of screening and education. Check out the resources available from the Global Fatty Liver Day public education campaign: globalfattyliverday.com. #ActNowScreenToday #FattyLiverDay #LiverHealth

Today, Akero announced the initiation of SYNCHRONY Outcomes, the third study in our Phase 3 SYNCHRONY trial program. We are actively recruiting patients with compensated cirrhosis, fibrosis stage 4 (F4) due to #MASH to take part in this global, randomized, placebo-controlled, 2-cohort, Phase 3 trial evaluating the efficacy and safety of #EFX. Read more here: https://lnkd.in/egxvSuz7 #ClinicalTrials

Akero announced today two #EFX updates at #EASLCongress 2024: a late-breaking analysis of the Week 96 results of the Phase 2b HARMONY trial and a post-hoc biomarker analysis showing the anti-fibrotic effects of EFX in patients with #MASH fibrosis F2-F3. Learn more here: https://lnkd.in/exrQk-d9. #EASL

Don’t miss our #efruxifermin presentations tomorrow at the #EASLCongress! We will share a late-breaking analysis of the Week 96 results of the Phase 2b HARMONY trial and a post-hoc biomarker analysis poster on the anti-fibrotic effects of #EFX. #EASL

Members of our Finance team had a blast together at an asylum themed escape room last week. Collaborating to solve challenges is what #TeamAkero is all about! Here's to many more adventures as we continue to push boundaries, break barriers, and forge stronger connections as a team.